ArticleIntelligence-based medicine2026
Diffusion models vs. DCGANs for class-imbalanced lung cancer CT classification: A comparative study.
Article in Intelligence-based medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficient transformer integration in nnU-Net for liver tumor segmentation: an external validation study.BMC medical imaging · 2026Article
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Effective lung cancer detection from CT scans remains critically challenged by class imbalance where benign and normal cases are underrepresented, leading to biased machine learning models with reduced sensitivity for minority classes and potentially missed diagnoses in cancer screening applications. We present a comprehensive comparative analysis of Diffusion Models and Deep Convolutional Generative Adversarial Networks (DCGANs), both incorporating modern architectural enhancements including spectral normalization, self-attention mechanisms, and conditional generation, for addressing class imbalance in lung cancer CT classification. Using the IQ-OTH/NCCD dataset comprising 1097 CT images across normal, benign, and malignant categories with statistical validation across 10 independent runs, we evaluated both approaches through quantitative image quality metrics (Fŕechet Inception Distance, Kullback-Leibler divergence, Kernel Inception Distance, and Inception Score) and downstream classification performance. While Diffusion models consistently outperformed DCGANs across most image quality measures, the clinical significance was confirmed through task-based validation. Both generative approaches successfully addressed class imbalance: DCGAN-augmented datasets achieved overall accuracy of 0.9760 ± 0.0116 with benign recall improvement from 0.833 to 0.933, while Diffusion-augmented datasets reached superior performance of 0.9959 ± 0.0068 with perfect benign recall (1.000 ± 0.000). Critically for cancer screening where false negatives carry severe consequences, Diffusion maintained the highest malignant detection sensitivity (0.997 ± 0.008) with substantially lower performance variance, demonstrating more consistent synthetic data quality. These findings establish that while both modern architectures can mitigate class imbalance, Diffusion models' superior recall performance and lower variability position them as the preferred approach for high-stakes clinical applications, demonstrating that ultimate validation must prioritize downstream clinical task performance over image quality metrics alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.